EFM
LXEO icon

E Fund Management’s Lexeo Therapeutics LXEO Stock Holding History

E Fund Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.8K Buy
+12,683
New +$89.9K ﹤0.01% 479

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

E Fund Management's LXEO Position: Q1 2026 in Review

E Fund Management opened a new position in Lexeo Therapeutics (LXEO) in Q1 2026: 12,683 shares worth $72.8K. The stake represents ﹤0.01% of the portfolio and ranks #479 among its holdings.

139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • E Fund Management held 12,683 shares of Lexeo Therapeutics worth $72.8K as of Q1 2026.
  • Lexeo Therapeutics was a new E Fund Management position in Q1 2026.
  • Lexeo Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q1 2026, its #479 holding.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.